Psychopharmacologic treatment of depression in the medically ill

被引:34
作者
Beliles, K
Stoudemire, A
机构
[1] Univ Nebraska, Dept Psychiat, Sch Med, Omaha, NE 68198 USA
[2] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA
[3] Creighton Univ, Omaha, NE 68178 USA
关键词
D O I
10.1016/S0033-3182(98)71339-8
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Appropriate selection of an antidepressant agent in medically ill patients requires a careful risk-benefit assessment matching the pharmacokinetic and pharmacodynamic properties of the drug being considered against the patient's physiological vulnerabilities, potential for drug interactions, and primary symptoms of the patient's depression. While in the past antidepressant drug selection was limited by the almost sole availability of the tricyclic antidepressants, newer drugs such as selective serotonin reuptake inhibitors, bupropion, and venlafaxine have vastly simplified treating depression in the medically ill. in refractory cases of depression in patients with medical illness, electroconvulsive therapy can be used with appropriate anesthetic management.
引用
收藏
页码:S2 / S19
页数:18
相关论文
共 91 条
  • [1] ABNORMAL PLATELET-AGGREGATION ASSOCIATED WITH FLUOXETINE THERAPY
    ALDERMAN, CP
    MORITZ, CK
    BENTOVIM, DI
    [J]. ANNALS OF PHARMACOTHERAPY, 1992, 26 (12) : 1517 - 1519
  • [2] FLUOXETINE KINETICS AND PROTEIN-BINDING IN NORMAL AND IMPAIRED RENAL-FUNCTION
    ARONOFF, GR
    BERGSTROM, RF
    POTTRATZ, ST
    SLOAN, RS
    WOLEN, RL
    LEMBERGER, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (01) : 138 - 144
  • [3] DYSKINESIA ASSOCIATED WITH FLUVOXAMINE
    ARYA, DK
    SZABADI, E
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1993, 13 (05) : 365 - 366
  • [4] BALDESSARINI RJ, 1990, ARCH GEN PSYCHIAT, V47, P191
  • [5] FLUOXETINE, FLUVOXAMINE AND EXTRAPYRAMIDAL TRACT DISORDERS
    BALDWIN, D
    FINEBERG, N
    MONTGOMERY, S
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1991, 6 (01) : 51 - 58
  • [6] EVALUATION OF THE POTENTIAL FOR INTERACTIONS OF PAROXETINE WITH DIAZEPAM, CIMETIDINE, WARFARIN, AND DIGOXIN
    BANNISTER, SJ
    HOUSER, VP
    HULSE, JD
    KISICKI, JC
    RASMUSSEN, JGC
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1989, 80 : 102 - 106
  • [7] BELILES KE, 1995, MED PSYCH P, V3, P1
  • [8] FLUVOXAMINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS
    BENFIELD, P
    WARD, A
    [J]. DRUGS, 1986, 32 (04) : 313 - 334
  • [9] THE EFFECTS OF RENAL AND HEPATIC-DISEASE ON THE PHARMACOKINETICS, RENAL TOLERANCE, AND RISK-BENEFIT PROFILE OF FLUOXETINE
    BERGSTROM, RF
    BEASLEY, CM
    LEVY, NB
    BLUMENFIELD, M
    LEMBERGER, L
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 (04) : 261 - 266
  • [10] BERLIN RM, 1984, AM J PSYCHIAT, V141, P582